DNA CHIP FOR DETECTION OF STAPHYLOCOCCUS AUREUS
    1.
    发明申请
    DNA CHIP FOR DETECTION OF STAPHYLOCOCCUS AUREUS 审中-公开
    用于检测油菜的DNA芯片

    公开(公告)号:US20100167951A1

    公开(公告)日:2010-07-01

    申请号:US12522392

    申请日:2007-01-08

    IPC分类号: C40B40/06 C07H21/04

    CPC分类号: C12Q1/689 C12Q1/6837

    摘要: The present invention relates to nucleic acid probes specific to Staphylococcus aureus, which is useful for detecting and identifying S. aureus in a biological sample. More particularly, the present invention relates to a DNA chip for detecting and identifying S. aureus, on which nucleic acid probes derived from 23 S rRNA gene of S. aureus are immobilized. The application of the DNA chips according to the present invention allows time-saving and accurate diagnosis of bacterial infection compared with the conventional bacterial culture methods.

    摘要翻译: 本发明涉及对金黄色葡萄球菌特异性的核酸探针,其可用于检测和鉴定生物样品中的金黄色葡萄球菌。 更具体地,本发明涉及用于检测和鉴定金黄色葡萄球菌的DNA芯片,其上固定有金黄色葡萄球菌23S rRNA基因的核酸探针。 与常规细菌培养方法相比,根据本发明的DNA芯片的应用允许节省细菌感染的准确诊断。

    MARKER AND METHOD FOR CANCER DIAGNOSIS
    2.
    发明申请
    MARKER AND METHOD FOR CANCER DIAGNOSIS 审中-公开
    癌症诊断标记和方法

    公开(公告)号:US20090269750A1

    公开(公告)日:2009-10-29

    申请号:US12161005

    申请日:2007-01-18

    IPC分类号: C12Q1/68 C07H21/00 C40B40/06

    摘要: The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3′-terminal end of exon 2 region linked to the 5′-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression.

    摘要翻译: 本发明涉及使用粒细胞集落刺激因子(G-CSF)基因变异的诊断性癌症标志物及其制备方法,更具体地涉及诊断癌症和/或评价癌症状态的方法 使用具有与G-CSF基因的外显子4区的5'末端连接的外显子2的3'末端的寡核苷酸作为诊断性癌症标志物进行。 根据本发明,可以使用G-CSF基因表达的变化快速且准确地诊断癌症。

    DNA CHIP FOR DIAGNOSIS OF CORNEAL DYSTROPHY
    3.
    发明申请
    DNA CHIP FOR DIAGNOSIS OF CORNEAL DYSTROPHY 审中-公开
    用于诊断角膜晶状体的DNA芯片

    公开(公告)号:US20090305394A1

    公开(公告)日:2009-12-10

    申请号:US12160965

    申请日:2007-01-18

    IPC分类号: C07H21/04 C12M1/34

    CPC分类号: C12Q1/6883 C12Q2600/156

    摘要: The present invention relates to oligonucleotides for diagnosis of corneal dystrophy. More particularly, the present invention relates to oligonucleotides for detecting mutation of BIGH3 gene for diagnosis or corneal dystrophy including Avellino corneal dystrophy, which must be precisely diagnosed before vision correction surgery, and a DNA chip for diagnosis of corneal dystrophy, which has the oligonucleotides fixed thereon. According to the present invention, conventional microscopic diagnosis of corneal dystrophy can be replaced with a precise genetic method, which prevents a patient with corneal dystrophy from losing eyesight by eyesight correction surgery after erroneous diagnosis.

    摘要翻译: 本发明涉及用于诊断角膜营养不良的寡核苷酸。 更具体地,本发明涉及用于检测用于诊断或角膜营养不良的BIGH3基因的突变的寡核苷酸,其包括在视力矫正手术之前必须精确诊断的Avellino角膜营养不良,以及用于诊断角膜营养不良的DNA芯片,其具有固定的寡核苷酸 上。 根据本发明,可以用精确的遗传方法代替常规的角膜营养不良症的微观诊断,其可以防止角膜营养不良患者在错误诊断后通过视力矫正手术而失去视力。

    Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody Against Tgf-Beta
    5.
    发明申请
    Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising an Antibody Against Tgf-Beta 审中-公开
    用于治疗包含抗Tgf-β的抗体的Avellino角膜营养不良的药物组合物

    公开(公告)号:US20080267946A1

    公开(公告)日:2008-10-30

    申请号:US11817023

    申请日:2006-03-08

    IPC分类号: A61K39/395 A61P27/02

    CPC分类号: C07K16/22 A61K2039/505

    摘要: The present invention relates to a medicine for treating Avellino corneal dystrophy (ACD), and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy containing an antibody against TGF-β as an effective ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms of a patient with severe Avellino corneal dystrophy due to TGF-β induced by exposure to intense light, such as UV etc.

    摘要翻译: 本发明涉及用于治疗阿维拉氏角膜营养不良症(ACD)的药物,更具体地,涉及含有抗TGF-β抗体作为有效成分的Avellino角膜营养不良药用组合物。 本发明的药物组合物具有通过暴露于强光如UV等引起的由TGF-β引起的严重的Avellino角膜营养不良症状改善的效果。

    Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum
    6.
    发明申请
    Pharmaceutical Composition for Treating Avellino Cornea Dystrophy Comprising Blood Plasma or Serum 审中-公开
    用于治疗包含血浆或血清的Avellino角膜营养不良的药物组合物

    公开(公告)号:US20080299212A1

    公开(公告)日:2008-12-04

    申请号:US11816999

    申请日:2006-02-24

    IPC分类号: A61K35/16

    CPC分类号: A61K35/16

    摘要: The present invention relates to a pharmaceutical agent for treating Avellino corneal dystrophy, and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy comprising pharmaceutically effective amount of blood plasma or serum as an active ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms by dissolving away hyaline granules in the cornea of a patient with severe Avellino corneal dystrophy due to LASIK surgery.

    摘要翻译: 本发明涉及一种用于治疗阿维拉氏角膜营养不良的药剂,更具体地,涉及包含药学有效量的血浆或血清作为活性成分的用于治疗阿维拉氏角膜营养不良的药物组合物。 本发明的药物组合物通过将透明颗粒溶解在由于LASIK手术引起的严重的Avellino角膜营养不良患者的角膜中而改善症状的效果。

    PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-BETA
    7.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-BETA 审中-公开
    用于治疗包含TGF-βA抗体的AVELLINO CORNEA DYSTROPHY的药物组合物

    公开(公告)号:US20100322947A1

    公开(公告)日:2010-12-23

    申请号:US12858241

    申请日:2010-08-17

    IPC分类号: A61K39/395 A61P27/02

    CPC分类号: C07K16/22 A61K2039/505

    摘要: The present invention relates to a medicine for treating Avellino corneal dystrophy (ACD), and more particularly, to a pharmaceutical composition for treating Avellino corneal dystrophy containing an antibody against TGF-β as an effective ingredient. The pharmaceutical composition of the present invention has an effect of improving symptoms of a patient with severe Avellino corneal dystrophy due to TGF-β induced by exposure to intense light, such as UV etc.

    摘要翻译: 本发明涉及一种用于治疗阿维拉氏角膜营养不良症(ACD)的药物,更具体地涉及用于治疗含有针对TGF-β1抗体的Avellino角膜营养不良的药物组合物。 作为有效成分。 本发明的药物组合物具有改善由于TGF-β受体导致的严重Avellino角膜营养不良患者症状的作用。 通过暴露于强光下,如紫外线等引起的